Global Latanoprost Market Overview:
The latanoprost eye drop is used to treat certain kinds of glaucoma. It is also used to treat a condition called hypertension of the eye alone or together with other medicines to lower pressure inside the eye that is caused by open-angle glaucoma or ocular (eye) hypertension. Latanoprost appears to work by increasing the outflow of fluid from the eye. This lowers the pressure in the eye. It belongs to a group of medicines called prostaglandins. The rising prevalence of glaucoma diseases is one of the major factors driving the growth of the market. According to AMA, the Global Latanoprost market is expected to see growth rate of 2.4% and may see market size of USD1.42 Billion by 2024.
- The Rising Prevalence of Glaucoma Diseases
- Increasing Geriatric Population Worldwide
- Growing Hypertension Prevalence among the People
- Several Adverse Effects Such As Darkening Of the Periocular Skin by the Use of Latanoprost
- Latanoprost Tends To Be Less Effective In Lowering IOP in Children than In Adults
- Research and Developments Activities Coupled with Drug Pipeline
- Emerging Demand from Developing Regions
Some of the key players profiled in the report are Pfizer (United States), Aerie Pharmaceuticals (United States), Mylan (United States), Novartis International AG (Switzerland), Teva Pharmaceutical Industries (Israel), S.C. ROMPHARM COMPANY S.R.L (Romania), Apotex (Canada), Sun Pharma (India) and CR Zizhu (China). Additionally, following companies can also be profiled that are part of our coverage like Laboratoire Riva (Canada), Taj Pharma (India), Sandoz (Germany) and Laboratoires Thea (France). Analyst at AdvanceMarketAnalytics see United States Players to retain maximum share of Global Latanoprost market by 2024. Considering Market by End Users, the sub-segment i.e. Pediatrics will boost the Latanoprost market. Considering Market by Bottle Size, the sub-segment i.e. 2.5 ml will boost the Latanoprost market.
On 13 March 2019, Aerie Pharmaceuticals Announced U.S. FDA Approval of Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the Reduction of Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension.
On 14 Sept 2018, Sun Pharma and SPARC Announce US FDA Approval of XELPROS to Treat Open-angle Glaucoma or Ocular Hypertension. XELPROS (latanoprost ophthalmic emulsion) 0.005% for topical ophthalmic use is the first and only benzalkonium chloride-free (BAK-free) form of latanoprost.
The March 2011, approval of generic latanoprost by the U.S. Food and Drug Administration and the consequent availability over generic latanoprost in other countries has significantly reduced the cost associated with the use of this drug and has made it a very practical option for reducing intraocular pressure in glaucoma and ocular hypertension patients in developing countries.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Latanoprost market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Latanoprost market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Latonoprost Manufacturers, Latonoprost Traders/Distributors, Latonoprost Importer/Exporter, Regulatory & Government Bodies, Research Institutes, Downstream Vendors, End Users and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.